Very low levels of ath- erogenic lipoproteins and the risk for cardiovascular events: a meta- analysis of statin trials. J Am Coll Cardiol. 2014;64:485 94. 3. THERAPEUTIC MODALITIES 3.1. Lifestyle Therapies 3.1.1. Diet Composition, Weight Control, and Physical Activity S3.1.1-1. Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S76 99. S3.1.1-2. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129:S102 38. S3.1.1-3. Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368:1279 90. S3.1.1-4. Lichtenstein AH, Appel LJ, Brands M, et al. Summary of American Heart Association diet and lifestyle recommendations revision 2006. Arterioscler Thromb Vasc Biol. 2006;26:2186 91. S3.1.1-5. Warburton DE, Charlesworth S, Ivey A, et al. A systematic review of the evidence for Canada s physical activity guidelines for adults. Int J Behav Nutr Phys Act. 2010;7:39. 3.1.2. Lifestyle Therapies and Metabolic Syndrome S3.1.2-1. Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007;49:403 14. S3.1.2-2. Kastelein JJ, Ginsberg HN, Langslet G, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015;36:2996 3003. S3.1.2-3. Alberti KG, Eckel RH, Grundy SM, et al. 